Jeena Sikho Lifecare (JSLL) Q4 24/25 earnings summary

Executive summary

• FY25 revenue from operations was ₹46,907.19 lakh, up 45% YoY; net profit was ₹9,072.89 lakh, up 31%.

• EBITDA increased 34% YoY to ₹124.88 crore, while EBITDA margin declined 204 bps to 27%.

• Operational capacity reached 1,600 beds, with 1,218 beds in the pipeline; FY25 IPD volumes grew 87% to 24,578.

• Auditors issued an unmodified opinion on the standalone annual financial results.

Financial highlights

• FY25 total income was ₹47,548.08 lakh versus ₹33,084.87 lakh in FY24; profit before tax was ₹12,206.71 lakh versus ₹9,391.71 lakh.

• FY25 gross profit was ₹410.84 crore, with an 88% gross margin, down 273 bps YoY.

• FY25 EBIT rose 32% to ₹116.17 crore; PAT margin was 19%, down 183 bps YoY.

• H2FY25 revenue increased 53% YoY to ₹254.94 crore; EBITDA rose 36% to ₹65.60 crore and PAT increased 17% to ₹43.85 crore.

• FY25 total expenses were ₹35,341.37 lakh, including ₹10,048.87 lakh in employee benefits and ₹21,244.91 lakh in other expenses.

Outlook and guidance

• Priorities include improving utilization of existing assets, launching new centres and adding beds at existing facilities.

• Plans include 15 product launches in the upcoming quarter and expanded OTC distribution, initially in Uttar Pradesh and then pan-India.

• Margin normalization is expected as revenue accrues from newly opened hospitals and the rollout pipeline.

• Growth plans include cashless insurance, expanded government and AYUSH panel coverage, and overseas expansion beginning with the UAE.